TLDR:
Chinese biotechs are seeing an influx of cash, particularly in late-stage assets, as investors, including state-owned venture capitals, show interest in the market. The Bio China International Convention in Suzhou highlighted the appeal of promising late-stage assets to Chinese investors.
Biotechs in China are starting to see cash flow again after a cold spell in recent years. Late-stage assets are garnering the most attention from investors, particularly Chinese state-owned venture capitals. Speakers at the Bio China International Convention in Suzhou emphasized the interest in promising late-stage assets in the Chinese biotech market.
Investors in China, especially state-owned venture capitals, are showing confidence in the market and are seeking opportunities in late-stage assets. The shift towards late-stage assets reflects a growing interest in established products with potential for success.
